Retrieve all available abstracts of the following 235 articles: HTML format
Single Articles
LI Z, Xia L, Li Y, Huang T, et al Diagnostic Values of Electrochemiluminescent Detection of Urinary CYFRA21-1 and
FDP and Their Combined Detection in Bladder Cancer.
Cancer Med. 2025;14:e71056. PubMed Abstract available
PATEL M, Rajagopalan A, Cahill EM, Chua KJ, et al Tolerability and efficacy of induction Bacillus Calmette-Guerin for non-muscle
invasive bladder cancer.
Bladder (San Franc). 2025;12:e21200031. PubMed Abstract available
ZHU H, Li J, Zhou X, Mi K, et al Advances in recombinant Bacillus Calmette-Guerin therapy for bladder cancer from
2015 to 2024: Innovations and challenges.
Bladder (San Franc). 2025;12:e21200047. PubMed Abstract available
HEGAZI MAAA, Pasqualini F, Chiriva-Internati M, Taverna G, et al SPEF1 and SPEF2 as potential biomarkers in bladder cancer: Insights from a
comprehensive bioinformatic analysis.
Bladder (San Franc). 2025;12:e21200039. PubMed Abstract available
JAFRI A, Hubbard R, Hussain SA Potential synergistic effect of radiotherapy and immune checkpoint inhibitors on
advanced bladder cancer: A case report.
Bladder (San Franc). 2025;12:e21200045. PubMed Abstract available
KORKES F, Santiago JHD, Pinto AMM, Farias ADS, et al Kidney function improvement after urinary diversion for cisplatin eligibility in
bladder cancer patients.
Bladder (San Franc). 2025;12:e21200027. PubMed Abstract available
HYLDGAARD J, Als AB, Ulhoi B, Jensen J, et al Assessment of lower urinary tract symptoms and their impact on quality of life
following radiation therapy for bladder cancer.
Bladder (San Franc). 2025;12:e21200033. PubMed Abstract available
WU Y, Zhang F, Ying Y, Li J, et al The role and clinical potential of RNA modifications in bladder cancer.
Bladder (San Franc). 2025;12:e21200037. PubMed Abstract available
ROESCH HRM, Jalalizadeh M, de Oliveira C, Reis LO, et al Trends in surgical procedures for bladder cancer within the Brazilian public
health system: An 11-year analysis.
Bladder (San Franc). 2025;12:e21200030. PubMed Abstract available
LIU C, Lu J, Lai J, Jie K, et al Advancements in genetic circuits as part of intelligent biotherapy for the
treatment of bladder cancer: A review.
Bladder (San Franc). 2025;12:e21200032. PubMed Abstract available
NIKOOBAKHT MR, Esmaeilpanah S, Menbari Oskouie I, Khoshchehreh M, et al Association of Thrombomodulin Expression with Bladder Cancer Grade, Stage, and
Recurrence: A Single-Center Prospective Pilot Study.
Iran J Pathol. 2025;20:266-272. PubMed Abstract available
QIN H, Hashem AF, Hanif MF, Fiidow OA, et al Graph theoretic and machine learning approaches in molecular property prediction
of bladder cancer therapeutics.
Sci Rep. 2025;15:28025. PubMed Abstract available
SHORE ND, Chevli KK, Saltzstein D, Ehrlich Y, et al Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer With
UGN-102: Outcomes From the 5-Year Long-Term Extension Study of the Single-Arm,
Phase 2b Optima II Study.
Clin Genitourin Cancer. 2025 Jun 25:102392. doi: 10.1016/j.clgc.2025.102392. PubMed Abstract available
BLACHE A, Huck C, Achard V, Coutte A, et al Hypofractionated radiotherapy in the management of bladder cancer.
Cancer Radiother. 2025;29. PubMed Abstract available
CHEN J, Hu M, Wang P, Lin R, et al MYEOV Facilitates the Progression of Bladder Cancer by Upregulating MMP9 Via the
TGF-beta-H3K4me3 Epigenetic Axis.
Mol Carcinog. 2025 Jul 31. doi: 10.1002/mc.70001. PubMed Abstract available
SHI MM, Guan MY, Li S, Guo JY, et al HOXC6-TIMELESS axis: Unveiling novel therapeutic strategies in bladder cancer.
World J Clin Oncol. 2025;16:108071. PubMed Abstract available
ZUO J, Chen J, Tan Z, Wen L, et al Comprehensive Mendelian randomization and colocalization analysis of plasma
proteomics to identify new therapeutic targets for bladder cancer.
J Cancer. 2025;16:3163-3179. PubMed Abstract available
MAHMOUD H, Abd El-Aziz AM, Ezzat O, Kenawy HI, et al Prediction of response to neoadjuvant chemotherapy in patients with
muscle-invasive urothelial bladder cancer: role of immune-related gene
expression.
Cancer Immunol Immunother. 2025;74:279. PubMed Abstract available
WAN X, Wang K, Ren P, Zhang X, et al Circadian Rhythm Genes-based Prognostic Signature for Bladder Cancer: Association
of EZH2 Expression with Anesthetic-related Changes in Circulating Tumor Cells.
Curr Med Chem. 2025 Jul 28. doi: 10.2174/0109298673362736250702043230. PubMed Abstract available
ZHAO Y, Xing Z, Zhao Y, Xu H, et al Lactylation prognostic signature identifies DHCR7 as a modulator of
chemoresistance and immunotherapy efficacy in bladder cancer.
Front Immunol. 2025;16:1585727. PubMed Abstract available
ATTANASIO G, Failla M, Poidomani S, Buzzanca T, et al Histological and immunohistochemical approaches to molecular subtyping in
muscle-invasive bladder cancer.
Front Oncol. 2025;15:1546160. PubMed Abstract available
RANJITH S, Thomas Jacob A, Augustine P, K C, et al Survival Outcomes in Bladder Cancer: An Ambispective Study of Patients Undergoing
Radical Cystectomy.
Cureus. 2025;17:e86938. PubMed Abstract available
SHEN C, Ni H, Chen Z, You J, et al Predictive model of double-J pipe scab size after radical total cystectomy based
on Boruta feature selection and LASSO technique: A retrospective cross-sectional
study.
Sci Prog. 2025;108:368504251363901. PubMed Abstract available
VRABIE CR, Parosanu AI, Nitipir C Sarcopenia in Urothelial Bladder Carcinoma: A Narrative Review.
Medicina (Kaunas). 2025;61:1307. PubMed Abstract available
CHO SY, Jung KT Adductor Muscle Contraction Under Deep Neuromuscular Blockade During TURBT Under
General Anesthesia: Is Obturator Nerve Block Still Necessary?-A Prospective,
Single-Arm, Exploratory Study.
Medicina (Kaunas). 2025;61:1207. PubMed Abstract available
Intravesical mitomycin (Zusduri) for bladder cancer.
Med Lett Drugs Ther. 2025;67:e128-e129. PubMed
SOLANO L Bladder cancer.
JAAPA. 2025;38:45-46. PubMed
HAMMAD G, Magdy M, Aboushousha T, Safwat G, et al Decreased Expression Levels Of PIWIL2, PIWIL3 and PIWIL4 Are Associated with Poor
Prognosis and Worse Survival in Bladder Cancer Patients.
Asian Pac J Cancer Prev. 2025;26:2467-2477. PubMed Abstract available
CHEN J, Yang X, Hao Z, Guo H, et al Extracellular vesicles-derived extracellular RNA in bladder cancer: current
progress and future prospects.
Ther Adv Med Oncol. 2025;17:17588359251349288. PubMed Abstract available
SUN L, Liu C, Cao Y, Li J, et al As a New Tumor Suppressor Gene, PID1 Activates the AMPK-mTOR Signal to Inhibit
the Progression of Bladder Cancer.
Res Rep Urol. 2025;17:235-248. PubMed Abstract available
TANG T, Kong S, Xie J, Deng Q, et al Prolonged Release of Bacillus Calmette-Guerin by Floating Microbubbles to Enhance
Intravesical Immunotherapy for Bladder Cancer.
ACS Nano. 2025 Jul 28. doi: 10.1021/acsnano.5c06540. PubMed Abstract available
DULF DV, Burnar AL, Dulf PL, Matei DR, et al Lymphovascular Invasion Is a Predictor of Clinical Outcomes in Bladder Cancer
Patients Treated with Radical Cystectomy.
J Clin Med. 2025;14:5120. PubMed Abstract available
PORRECA A, Marino F, De Marchi D, Crestani A, et al Robot-Assisted Radical Cystectomy with Ureterocutaneostomy: A Potentially Optimal
Solution for Octogenarian and Frail Patients with Bladder Cancer.
J Clin Med. 2025;14:4898. PubMed Abstract available
AHMED MY, Cakir MO, Sandhu S, Ashrafi GH, et al Detection of High-Risk Human Papillomavirus in Bladder Cancer: An Exploratory
Study from a UK-Based Population.
Biomedicines. 2025;13:1548. PubMed Abstract available
TANAKA S, Shimizu T, Pagano I, Hogrefe W, et al Expanded Performance Comparison of the Oncuria 10-Plex Bladder Cancer Urine Assay
Using Three Different Luminex xMAP Instruments.
Diagnostics (Basel). 2025;15:1749. PubMed Abstract available
ZHANG DY, Sali R, Zhu M, Zhang V, et al Introduction of an Integrated Pathology Image Management, Artificial
Intelligence, and Reporting System.
J Vis Exp. 2025;. PubMed Abstract available
PENG J, Li D, Xiang B, Li Z, et al Knockdown of CSF1R molecules enhances the antitumor effects of CD8(+) T
lymphocytes in bladder cancer.
Discov Oncol. 2025;16:1426. PubMed Abstract available
MARTIN R, Wylie H, Moss C, Hafeez S, et al Understanding oncological and sexual function outcomes with gynaecological organ
preserving cystectomy in women with bladder cancer; a systematic review.
BJUI Compass. 2025;6:e70053. PubMed Abstract available
PASSOS L, Dabravolskaite V, Kotelis D, Makaloski V, et al Successful complex endovascular treatment of a contained rupture of a
thoracoabdominal aortic aneurysm caused by Mycobacterium bovis after intravesical
Bacillus Calmette-Guerin immunotherapy for bladder cancer.
J Vasc Surg Cases Innov Tech. 2025;11:101895. PubMed Abstract available
FENTON D, Han S, Lee A, Perez AH, et al A Case of Malignant Priapism Secondary to Muscle Invasive Bladder Cancer and
Review of Palliative Management.
Case Rep Urol. 2025;2025:2340917. PubMed Abstract available
MILLING RV, Nielsen NK, Graugaard-Jensen C, Christensen P, et al Long-term effect of treatment for non-muscle invasive bladder cancer on Quality
of life: a cross-sectional study.
Scand J Urol. 2025;60:141-147. PubMed Abstract available
TORIKKA SUUA S, Porserud A, Nygren-Bonnier M, Hagstromer M, et al Association between physical function before radical cystectomy for urinary
bladder cancer and recovery after discharge from hospital.
Scand J Urol. 2025;60:135-140. PubMed Abstract available
SZOSTEK A, Khadhouri S, Gallagher KM, MacKenzie KR, et al Bladder cancer prevalence and diagnostic test accuracy: French results from the
IDENTIFY study.
Fr J Urol. 2025 Jul 24:102935. doi: 10.1016/j.fjurol.2025.102935. PubMed Abstract available
ZHAO X, Wang X, Wu G Letter to editor: SRSF1-mediated alternative splicing regulates bladder cancer
progression and cisplatin sensitivity through HIF1A/BNIP3/mitophagy axis.
J Transl Med. 2025;23:839. PubMed
FERRO M, Crocetto F, Jannello LMI, Contieri R, et al Emerging biomarkers in bladder cancer: Translating molecular advances into
precision oncology.
Crit Rev Oncol Hematol. 2025;215:104862. PubMed Abstract available
ZHANG L, Tian J, Huang H Primary Extranodal Natural Killer/T-cell Lymphoma of the Bladder on 18F-FDG
PET/CT.
Clin Nucl Med. 2025 May 13. doi: 10.1097/RLU.0000000000005956. PubMed Abstract available
GHORBANI H, Saber Tanha A, Ataei N, Ataei R, et al Metastasis of Urothelial Carcinoma to the Wrist: A Case Report of an Overlooked
Finding on Whole-body 99m Tc-MDP Scan.
Clin Nucl Med. 2025;50:e561-e563. PubMed Abstract available
YOSHIDA T, Nakano Y, Kitada M, Nakamoto T, et al Ultrasound-guided obturator nerve block technique at the distal end of the
obturator canal: case series and cadaver evaluation.
J Anesth. 2025;39:652-656. PubMed Abstract available
LU K, Chao L, Wang J, Wang X, et al Risk Score Model of Aging-Related Genes for Bladder Cancer and Its Application in
Clinical Prognosis.
JCO Clin Cancer Inform. 2025;9:e2500019. PubMed Abstract available
DE ANDREA CE, Abengozar-Muela M, Arranz JA, Climent MA, et al Association of PD-1, LAG-3 and TIM-3 expression on intratumoral CD8 T-cells with
response to atezolizumab in a Real-World-Evidence biomarker study for advanced
urothelial carcinoma patients.
Oncoimmunology. 2025;14:2538687. PubMed Abstract available
RODRIGUEZ PENARANDA N, Falkenbach F, Marmiroli A, Longoni M, et al Contemporary rates and predictors of prolonged hospital stay after radical
cystectomy: a population-based analysis.
World J Urol. 2025;43:478. PubMed Abstract available
CHUN H, Baima K Unraveling the dual role of METTL3-mediated m(6)A RNA modification in bladder
cancer: mechanisms, therapeutic vulnerabilities, and clinical implications.
Cancer Biol Ther. 2025;26:2545057. PubMed Abstract available
ABDERRAHMANE RK, Touala-Chaila Z, Benseddik K, Hassani N, et al Are TP53 Arg72Pro and MDM2 T309G polymorphisms associated with bladder cancer
risk? A meta-analysis.
Afr Health Sci. 2024;24:118-127. PubMed Abstract available
KAYNAR K, Misir B, Ataberk HC, Mungan S, et al Long live the kidney despite every threats: a case report.
Pan Afr Med J. 2025;51:35. PubMed Abstract available
FENG X, Huang J Temozolomide Resistance in Smoking-Related Bladder Cancer through
TNFAIP6-Mediated Post-Translational Modifications.
Arch Esp Urol. 2025;78:732-742. PubMed Abstract available
KAYAR R, Kayar K, Tokuc E, Topaktas R, et al Value of Preoperative Inflammatory Burden Index in Predicting Overall Survival
and Progression in Nonmetastatic Muscle-Invasive Bladder Cancer.
Arch Esp Urol. 2025;78:660-670. PubMed Abstract available
JIE Y, Yang Y, Guo C, Wu Q, et al The TCF7L2/miR-206/Cofilin1 axis promotes the metastasis of bladder cancer cells
by regulating the formation of invadopodia.
Acta Biochim Biophys Sin (Shanghai). 2025 Aug 6. doi: 10.3724/abbs.2025114. PubMed Abstract available
DAS A, Diala C, Chen G, Li Z, et al Efficient Training Corpus Retrieval for Large Language Model Fine Tuning: A Case
Study in Cancer.
Stud Health Technol Inform. 2025;329:1251-1255. PubMed Abstract available
HUANG W, Li L, Chao F, Yang Q, et al [(64)Cu]Cu-NOTA-EV-F(ab')(2) Enables Same-Day Immuno-PET Imaging of Nectin-4 in
Triple-Negative Breast and Urothelial Bladder Cancers.
J Nucl Med. 2025 Aug 7:jnumed.125.270132. doi: 10.2967/jnumed.125.270132. PubMed Abstract available
ZHANG L, Jin D, Zang J, Qian L, et al Disitamab vedotin combined with toripalimab and radiotherapy for multimodal
organ-sparing treatment of muscle invasive bladder cancer: a proof-of-concept
study.
Neoplasia. 2025;68:101216. PubMed Abstract available
YUEN K, Meagher M, Mercer J, Yilma B, et al Comprehensive Comparison of Somatic, Germline, and Immune Cell Profiles in Upper
Tract and Bladder Urothelial Carcinoma.
JCO Precis Oncol. 2025;9:e2500289. PubMed Abstract available
LIANG X, Liu Q, Sun X Comment on "Long-term impact of synchronous and metachronous bladder cancer on
prognosis after radical nephroureterectomy for upper urinary tract urothelial
carcinoma: results from a large population-based cohort in China.
Int J Surg. 2025 Aug 7. doi: 10.1097/JS9.0000000000003146. PubMed
ZENG Q, Cheng Y, Wang C, Chao H, et al Genetic influence of coffee intake on bladder cancer risk: a two-sample Mendelian
randomization analysis.
Food Funct. 2025 Aug 7. doi: 10.1039/d4fo05538. PubMed Abstract available
SHAN L, Liu W, Zhan Y Retraction Note: LncRNA HAND2-AS1 exerts anti-oncogenic effects on bladder cancer
via restoration of RARB as a sponge of microRNA-146.
Cancer Cell Int. 2025;25:298. PubMed
LIU Y, Xu W, Qin X, Zheng J, et al Intravesical delivery of mucoadhesive and tumor-selective-penetrating nanozymes
for enhancing the PDT of bladder cancer.
J Nanobiotechnology. 2025;23:554. PubMed Abstract available
ZHANG X, Cong Y, Zheng X, Wu G, et al Letter to editor: SIGMAR1 screened by a GPCR-related classifier regulates
endoplasmic reticulum stress in bladder cancer.
J Transl Med. 2025;23:874. PubMed Abstract available
HUANG Y, Fang S, Xie W, Zou Y, et al Collagen gene signature in the tumor microenvironment predicts survival and
guides prognosis in bladder cancer.
Discov Oncol. 2025;16:1479. PubMed Abstract available
NI B, Li S, Zhao L, Gao L, et al Novel glycoprotein SBSPON suppressed bladder cancer through the AKT signal
pathway by inhibiting HSPA5 membrane translocation.
Int J Biol Sci. 2025;21:4586-4603. PubMed Abstract available
ARIMA J, Yoshino H, Tatarano S, Mitsuke A, et al Prognostic Impact of Clostridium butyricum MIYAIRI (CBM588) in Combination With
Pembrolizumab for Advanced Urothelial Carcinoma: A Retrospective Cohort Study.
Cancer Rep (Hoboken). 2025;8:e70308. PubMed Abstract available
WANG Y, Sun Y, Guan L, Yang Y, et al Risk of secondary bladder cancer after postoperative radiotherapy for rectal
cancer: A population-based cohort study.
Radiography (Lond). 2025 Aug 4:103112. doi: 10.1016/j.radi.2025.103112. PubMed Abstract available
HUSSEIN S, Waley AB, Abdelgeleel HM, Saadawy SF, et al LC3 and beclin-1 immunohistochemical and gene expressions in bladder cancer.
Clin Transl Oncol. 2025 Aug 5. doi: 10.1007/s12094-025-04002. PubMed Abstract available
FAN L, Zhou Y, Liu S, Zhuo X, et al NR4A3 regulates anoikis resistance and metastasis of bladder cancer through
EWSR1.
Cancer Biol Ther. 2025;26:2535774. PubMed Abstract available
GINWALA R, Bukavina L, Sindhani M, Nachman E, et al Bladder cancer microbiome and its association with chemoresponse.
Front Oncol. 2025;15:1506319. PubMed Abstract available
NAKATANI M, Sasaki T, Sawai C, Inaba S, et al [A Case of Paraneoplastic Neurological Syndrome Caused by Bladder Cancer
Manifesting as Limbic Encephalitis].
Hinyokika Kiyo. 2025;71:239-243. PubMed Abstract available
GUO Z, Wang W, Hu W, You W, et al Chemotherapeutic dihydromyricetin with remarkable anti-tumor activity and
biosafety for muscle invasive bladder cancer.
Front Pharmacol. 2025;16:1609354. PubMed Abstract available
YOU C, Zhang J, Lei J, Fu W, et al Cost-effectiveness of perioperative durvalumab plus neoadjuvant chemotherapy for
muscle invasive bladder cancer in the United States.
Ther Adv Med Oncol. 2025;17:17588359251357519. PubMed Abstract available
XU Z, Yang J, Ma Y, Tao B, et al Exploring of bladder cancer immune-related genes and potential therapeutic
targets based on transcriptomic data and Mendelian randomization analysis.
Front Immunol. 2025;16:1607098. PubMed Abstract available
Correction to "Targeting the KAT8/YEATS4 Axis Represses Tumor Growth and
Increases Cisplatin Sensitivity in Bladder Cancer".
Adv Sci (Weinh). 2025 Aug 4:e13864. doi: 10.1002/advs.202513864. PubMed
MIAO Q, Hong B, Zhang X, Sun Z, et al [Risk assessment of perioperative adverse events and management of antiplatelet
therapy in patients with bladder cancer and coronary atherosclerotic heart
disease undergoing transurethral resection of bladder cancer].
Beijing Da Xue Xue Bao Yi Xue Ban. 2025;57:698-703. PubMed Abstract available
DESANTO M, Campanelli J, Deem S Repeat TURBT for Ta and T1 bladder cancer: An updated review.
Urol Oncol. 2025 Aug 2:S1078-1439(25)00257-1. doi: 10.1016/j.urolonc.2025. PubMed Abstract available
LIN L, Liu Z, Tang Y, Lin T, et al Exploring the Impact of 5-Alpha Reductase Inhibitors on Bladder Cancer: Insights
from a Large-Scale Prospective Cohort Study.
Ann Surg Oncol. 2025 Aug 3. doi: 10.1245/s10434-025-17981. PubMed Abstract available
WANG H, Yang L Re: Mariana Silva-Ferreira, Joao A. Carvalho, Sofia Salta, et al. Diagnostic Test
Accuracy of Urinary DNA Methylation-based Biomarkers for Bladder Cancer:
Considerations for Further Research. Eur Urol Focus 2024;10:922-34.
Eur Urol Focus. 2025 Aug 2:S2405-4569(25)00241-X. doi: 10.1016/j.euf.2025. PubMed
EL-SAWY L, Rubin JR, Broses L, Patsalis C, et al The molecular mechanism of ambrosin induced cytotoxicity of human breast cancer
and bladder cancer cells.
J Biol Chem. 2025 Aug 1:110531. doi: 10.1016/j.jbc.2025.110531. PubMed Abstract available
MAGGI M, Chierigo F, Fallara G, Jannello LMI, et al Shaping the Future of Personalized Therapy in Bladder Cancer Using Artificial
Intelligence.
Eur Urol Focus. 2025 Aug 1:S2405-4569(25)00216-0. doi: 10.1016/j.euf.2025. PubMed Abstract available
LEE J, Chen F, Lopez-Beltran A, Necchi A, et al Urinary Tumor DNA-based Liquid Biopsy in Bladder Cancer Management: A Systematic
Review.
Eur Urol Focus. 2025 Aug 1:S2405-4569(25)00178-6. doi: 10.1016/j.euf.2025. PubMed Abstract available
GABRIEL PE, Roumiguie M, Marcq G, Allory Y, et al The Evolving Landscape of Systemic Immunotherapy for Bacillus
Calmette-Guerin-naive High-risk Non-muscle-invasive Bladder Cancer: At the Edge
of a Tsunami?
Eur Urol Oncol. 2025 Aug 1:S2588-9311(25)00174-9. doi: 10.1016/j.euo.2025. PubMed Abstract available
ULLAH S, Gul L, Yousuf SB, Hassan B, et al Evaluating postoperative complications in radical cystectomy and ileal conduit
for bladder cancer using the clavien-dindo grading system.
J Pak Med Assoc. 2025;75:1053-1057. PubMed Abstract available
HATAKEYAMA S, Yamamoto H, Kitamura H, Kamoto T, et al Safety of Robot-Assisted Radical Cystectomy for Muscle-Invasive Bladder Cancer: A
Real-World Analysis Using the National Clinical Database in Japan.
Cancer Med. 2025;14:e71109. PubMed Abstract available
VENKATESH A, Ishiyama Y, Rodriguez Rosales RD, Kanumuambidi JP, et al An RMST-based analysis of systemic therapy in muscle-invasive bladder cancer.
Urol Oncol. 2025 Jul 31:S1078-1439(25)00252. PubMed Abstract available
PICCOLINI A, Contieri R, Uleri A, Moretto S, et al Assessing oncological outcomes of bladder-sparing treatments in patients with
BCG-unresponsive and BCG-exposed non-muscle-invasive bladder cancer.
Urol Oncol. 2025 Jul 31:S1078-1439(25)00253. PubMed Abstract available
YEARY KHK, Kuliszewski MG, Yu H, Li Q, et al Description of a cruciferous vegetable intervention trial to test the efficacy of
a maintenance component to reduce bladder cancer recurrence and progression.
Contemp Clin Trials. 2025;156:108036. PubMed Abstract available
HOLT MV, Dou Y, Young MN, Saltzman AB, et al Proteogenomic characterization unveils biomarkers associated with chemoresistance
in muscle-invasive bladder cancer.
Cell Rep Med. 2025 Jul 29:102255. doi: 10.1016/j.xcrm.2025.102255. PubMed Abstract available
YAMAMOTO S, Fukuhara H, Shigehisa R, Hara T, et al Clinical utility of photodynamic diagnosis with 5-aminolevulinic acid
hydrochloride for detecting carcinoma in situ independent of urine cytology
classification.
Photodiagnosis Photodyn Ther. 2025;54:104722. PubMed Abstract available
FANG P, Yu Y, Ma Y, Yan Y, et al The novel ferroptosis-inducing molecule can inhibit the progression of BC by
regulating the ubiquitination of UHRF1.
Epigenomics. 2025;17:777-791. PubMed Abstract available
LEE T, Gianchandani A, Boorjian SA, Shore ND, et al Intravesical interferon-alpha2b gene therapy with nadofaragene firadenovec-vncg: a
contemporary review.
Future Oncol. 2025;21:2429-2438. PubMed Abstract available
AGUIRRE LS, Barbeito CG, Medina DM, Colque Caro LA, et al Urinary bladder lesions of bovine enzootic hematuria in Argentina.
Res Vet Sci. 2025;193:105797. PubMed Abstract available
FUKUHARA H, Shigehisa R, Saito K, Hara T, et al Risk factors of severe prolonged hypotension induced by 5-aminolevulinic acid
during photodynamic diagnosis-assisted transurethral resection of bladder tumor.
Photodiagnosis Photodyn Ther. 2025;54:104667. PubMed Abstract available
LI Y, Kanber Y, Caglar D, Kassouf W, et al The Spectrum of Polyoma Virus and Polyoma Virus-Like Changes in Urine Cytology:
When Should an Atypical Diagnosis Be Considered.
Diagn Cytopathol. 2025;53:447-453. PubMed Abstract available
ANDO H, Takao K, Honda M, Kubota S, et al A case of irAE myositis with positive antistriational antibodies after anti-PD-L1
antibody administration: A case report.
Mod Rheumatol Case Rep. 2025;9:rxaf025. PubMed Abstract available
LEE S, Sfanos K, Singla N The role of the urinary microbiome in genitourinary cancers.
Nat Rev Urol. 2025;22:544-561. PubMed Abstract available
YI B, Zhao Z, Gao X, Zhao D, et al Antimony Exposure Induces Bladder Cancer Metastasis Via Activation of the
SUMOylation-Dependent TGF-beta/Smad2/3 Axis.
Environ Res. 2025 Aug 12:122589. doi: 10.1016/j.envres.2025.122589. PubMed Abstract available
SEOK J, Kwak HJ, Kang CK, Kim AR, et al Corrigendum to 'Development of a Technique for Diagnosis and Screening of
Superficial Bladder Cancer by Cell-Pellet DNA From Urine Sample' [Laboratory
Investigation 105 (2025) 104124].
Lab Invest. 2025;105:104225. PubMed
XU J, Wang G, Wang M, Xu X, et al Pedunculoside regulates tumor immune microenvironment and malignant
characteristics of bladder cancer by TRAF6 mediated M2 macrophage polarization.
Int Immunopharmacol. 2025;164:115301. PubMed Abstract available
LI Z, Jiang Q, Yang Q, Zhou Y, et al Hypoxia-induced PYCR1 regulates glycolysis and histone lactylation to promote
bladder cancer progression and metastasis via SLC6A14/Glutamine metabolism.
Cancer Biol Ther. 2025;26:2546219. PubMed Abstract available
PAVALEAN MI, Dobre M, Pelisenco IA, Madan VL, et al Association of miRNA-17-92 Cluster with Muscle Invasion in Bladder Cancer.
Int J Mol Sci. 2025;26:7546. PubMed Abstract available
PUIA D, Ivanuta M, Pricop C DNA Methylation in Bladder Cancer: Diagnostic and Therapeutic Perspectives-A
Narrative Review.
Int J Mol Sci. 2025;26:7507. PubMed Abstract available
GOMEZ BB, Casas-Nebra FJ, Perez-Fentes D, Bravo SB, et al Variations in Circulating Tumor Microenvironment-Associated Proteins in
Non-Muscle Invasive Bladder Cancer Induced by Mitomycin C Treatment.
Int J Mol Sci. 2025;26:7413. PubMed Abstract available
FLORES-ESTRADA JJ, Jimenez A, Victoria-Acosta G, Cortes-Malagon EM, et al Nuclear Receptors in Bladder Cancer: Insights into miRNA-Mediated Regulation and
Potential Therapeutic Implications.
Int J Mol Sci. 2025;26:7340. PubMed Abstract available
DAVIS E, Caggiano LJ, Munholland H, Basu R, et al Growth Hormone Signaling in Bladder Cancer: Transcriptomic Profiling of Patient
Samples and In Vitro Evidence of Therapy Resistance via ABC Transporters and EMT
Activation.
Int J Mol Sci. 2025;26:7113. PubMed Abstract available
PALENCIA PS, Sivanesan N, Rahman S, Ghali F, et al Partial Cystectomy for Muscle-Invasive Bladder Cancer.
Cancers (Basel). 2025;17:2562. PubMed Abstract available
RAHMAN SN, Martin DT, Keervani K, James S, et al Evaluating the Therapeutic Role of Lymph Node Dissection in Variant Subtype
Bladder Cancer.
Cancers (Basel). 2025;17:2536. PubMed Abstract available
SHYR CR, Wu CF, Yang KC, Ma WL, et al Evaluating Therapeutic Efficacy of Intravesical Xenogeneic Urothelial Cell
Treatment Alone and in Combination with Chemotherapy or Immune Checkpoint
Inhibition in a Mouse Non-Muscle-Invasive Bladder Cancer Model.
Cancers (Basel). 2025;17:2448. PubMed Abstract available
YILDIZ HA, Deger MD, Aslan G How Accurately Can Urologists Predict Eligible Patients for Immediate
Postoperative Intravesical Chemotherapy in Bladder Cancer?
Diagnostics (Basel). 2025;15:1856. PubMed Abstract available
LU K, Chao L, Wang J, Wang X, et al Suppressive effects of Momordica charantia MAP30 on the senescence, proliferation
and migration of bladder cancer cells mediated by CENPA.
Sci Rep. 2025;15:29679. PubMed Abstract available
KATARI V, Dalal K, Kondapalli N, Paruchuri S, et al Transient receptor potential vanilloid type 4 channels mediate bladder cancer
cell proliferation, migration, and chemoresistance.
J Pharmacol Exp Ther. 2025;392:103665. PubMed Abstract available
JI N, Hassouneh Z, Trecarten S, Shu ZJ, et al A Double-Humanized Murine Model in Bladder Cancer: A Novel Preclinical Model for
Cancer Immunology Research.
Cancer Med. 2025;14:e71150. PubMed Abstract available
YANG F, Qiu K, Deng J Unveiling SNX10: a key player in bladder cancer progression.
Transl Androl Urol. 2025;14:1912-1924. PubMed Abstract available
CHEN Y, Xian P, Lu J, Zhang L, et al Purine Nucleoside Phosphorylase (PNP) as a Biomarker and Therapeutic Target in
Muscle-Invasive Bladder Cancer.
Clin Med Insights Oncol. 2025;19:11795549251359145. PubMed Abstract available
HE Z, Gong C, Gu J, Wang W, et al Potential of APOBEC3B as a therapeutic target and its role in bladder cancer
onset and progression.
Eur J Med Res. 2025;30:740. PubMed Abstract available
HAN Y, Liu C, Wu G Letter to the editor: Prognostic biomarker PSMD14 facilitates bladder cancer
tumorigenesis and progression by regulating Nucleolin-YAP1 axis.
Transl Oncol. 2025;61:102498. PubMed
YANG Y, Chen Y, Liu Q, Guan L, et al Fusobacterium nucleatum promotes bladder cancer progression and immune escape by
activating the IL22/STAT3/PD-L1 signaling cascade.
Tissue Cell. 2025;97:103065. PubMed Abstract available
ZHANG Q, Zhai T, Chen J, Chen Z, et al Integrated photoelectrochemical/photothermal dual-mode biosensor with
simultaneous dual-signal output for detection of bladder cancer cells HT-1376.
Bioelectrochemistry. 2025;167:109075. PubMed Abstract available
ZHANG X, Zhang H, Shang P Comment on "innovative logic 'AND' gate gene circuits for bladder cancer
treatment: preclinical study".
Int J Surg. 2025 Aug 11. doi: 10.1097/JS9.0000000000003080. PubMed
GUERRERO QUILES C, Fahy S, Bartak M, Gonzalez Abalos J, et al Radiation-induced extracellular matrix remodelling drives prognosis and predicts
radiotherapy response in muscle-invasive bladder cancer.
Front Oncol. 2025;15:1616943. PubMed Abstract available
XU X, Yan M, Xie Z, Zhang Y, et al Identification and validation of a novel signature based on M2 macrophage
co-expressed genes in bladder cancer.
Transl Cancer Res. 2025;14:4194-4207. PubMed Abstract available
GOEL A, Tura BJ, Stockton JD, Tovey N, et al Detection of genome-wide methylation changes in bladder cancer by long-read
sequencing of urinary DNA.
Clin Epigenetics. 2025;17:141. PubMed Abstract available
YAMAMOTO K, Yamamoto K, Juri H, Azuma H, et al Vesical perfusion volume and internal iliac pressure during double
balloon-occluded arterial infusion chemotherapy for bladder cancer.
Eur Radiol Exp. 2025;9:72. PubMed Abstract available
ZHU G, He Y, Wang S, Huang J, et al Extraperitoneal vs transperitoneal laparoscopic cystectomy: optimized surgical
techniques and long-term outcomes in a single-center retrospective cohort study.
World J Surg Oncol. 2025;23:310. PubMed Abstract available
XIAO J, Liu J, Zhang C, Liu Z, et al Overcoming immunotherapy resistance in bladder cancer with a novel antibody-drug
conjugate RC48.
J Immunother Cancer. 2025;13:e011881. PubMed Abstract available
BATRA R, Yadav S, Chaure M, Garg S, et al Bladder preserving approach for treatment of primary osteogenic sarcoma of
bladder: A rare case report.
Indian J Cancer. 2025;62:305-307. PubMed Abstract available
CHENG TY, Chiu YC, Chen KH, Chen YJ, et al Correction: Galactosylated silver nanoparticles as a biocompatible intrinsic SERS
probe for bladder cancer imaging and ex vivo tumor detection.
J Mater Chem B. 2025 Aug 11. doi: 10.1039/d5tb90125. PubMed Abstract available
LEE H, Kwon H, Kim CW Minimizing Blood Loss in Bladder Cancer: Efficacy of Preoperative Embolization
before Transurethral Resection of Bladder Tumor.
J Korean Soc Radiol. 2025;86:512-523. PubMed Abstract available
GAO F, Yao L, Teng J, Zhao F, et al The Temporal Trends and Attributed Risk Burden of Kidney Cancer, Bladder Cancer,
and Prostate Cancer in China From 1990 to 2021.
Cureus. 2025;17:e87583. PubMed Abstract available
ZHOU XD, Shi N, Wang JJ, Wang X, et al [Expressions of androgen receptor and human epidermal growth factor receptor 2 in
urinary bladder urothelial carcinoma with incidental prostate cancer and
clinicopathological features of the malignancy].
Zhonghua Nan Ke Xue. 2024;30:1081-1085. PubMed Abstract available
LIN L, Lin T, Li X, Wang X, et al ASO Author Reflections: The Complex Role of 5-Alpha Reductase Inhibitors in
Bladder Cancer.
Ann Surg Oncol. 2025 Aug 9. doi: 10.1245/s10434-025-18073. PubMed
DU Y, Li H, Sui Y, Tao Y, et al Habitat-based radiomic model for predicting muscle invasion in bladder cancer: A
multi-center study using enhanced-CT and machine learning.
Med Phys. 2025;52:e18021. PubMed Abstract available
HO M, Lazarovich A, Saoud R, Dahmen A, et al Bacillus Calmette-Guerin (BCG) in combination with PANVAC vs. BCG alone in
adults with high-grade BCG-refractory non-muscle-invasive bladder cancer.
Urol Oncol. 2025 Aug 7:S1078-1439(25)00222-4. doi: 10.1016/j.urolonc.2025. PubMed Abstract available
MINIKES AM, Liu P, Wang H, Hu J, et al HIF-independent oxygen sensing via KDM6A regulates ferroptosis.
Mol Cell. 2025;85:2973-2987. PubMed Abstract available
SEKERES M, Lengle D, Abbey L, Kassack MU, et al Epigenetic targeting of DNA damage response (DDR)-related mechanisms to overcome
acquired cisplatin resistance of tumor cells.
Biochim Biophys Acta Mol Cell Res. 2025;1872:120018. PubMed Abstract available
MAUGER DE VARENNES A, Mermier M, Khene ZE, Gasmi A, et al Robot-assisted tubeless radical cystectomy: Is the absence of ureteral drainage a
mistake?
Fr J Urol. 2025;35. PubMed Abstract available
LAGOS-VILLASECA A, Koshkin VS, Kinet MJ, Rosen CA, et al Laryngeal Mucous Membrane Pemphigoid as an Immune-related Adverse Effect of
Pembrolizumab Treatment.
J Voice. 2025;39:890-895. PubMed Abstract available
LAI S, Wu P, Liu J, Song Y, et al Assessing the Influence of Bladder Cancer on Upper Tract Urothelial Carcinoma
Prognoses Following Radical Nephroureterectomy: A Retrospective, Propensity
Score-Based Multicenter Cohort Study.
Ann Surg Oncol. 2025 Aug 25. doi: 10.1245/s10434-025-17808. PubMed Abstract available
NEDJADI T, Ahmed ME, Ansari HR, Aouabdi S, et al The clinical value of the EpCAM biomarker and its association with immune cell
infiltration in bladder cancer.
Diagn Pathol. 2025;20:96. PubMed Abstract available
HOOSHMAND F, Mokhtari M, Aminnia S, Dashtestani A, et al PD-1 and PD-L1 expression in molecular subtypes of muscle-invasive bladder
cancer: immunohistochemical characterization and correlation with
clinicopathological features.
Diagn Pathol. 2025;20:97. PubMed Abstract available
ALSOUFI F, Zetoune AB High mobility group A2 (HMGA2) protein tissue levels and its association with
clinicopathological features in bladder cancer patients.
Discov Oncol. 2025;16:1622. PubMed Abstract available
FAN G, Zhu X, Chen Y, Cai S, et al Comparative outcomes of intracorporeal and extracorporeal urinary diversion in
robotic cystectomy: a systematic review and meta-analysis.
J Robot Surg. 2025;19:512. PubMed Abstract available
RETRACTION: SENP2 Suppresses Epithelial-Mesenchymal Transition of Bladder Cancer
Cells Through deSUMOylation of TGF-betaRI.
Mol Carcinog. 2025 Aug 25. doi: 10.1002/mc.70038. PubMed Abstract available
RETRACTION: Silencing Circular RNA VANGL1 Inhibits Progression of Bladder Cancer
by Regulating miR-1184/IGFBP2 Axis.
Cancer Med. 2025;14:e71178. PubMed Abstract available
HASSAN IN, Ibrahim MNH, Abuassa N FDA approves durvalumab for muscle-invasive bladder cancer: a new standard in
neoadjuvant and adjuvant therapy.
Ann Med Surg (Lond). 2025;87:4011-4013. PubMed
WANG G, Han M, Chen F, Liu J, et al LINC00152 knockdown exerts repressive effects on epithelial-mesenchymal
transition in bladder cancer.
Cytotechnology. 2025;77:166. PubMed Abstract available
XU K, Gu D, Zhang Y, Su Q, et al Engineering Schottky Junction Nanocatalysts for Enhanced Charge Carrier
Separation and Synergistic PDT/PTT/CDT in Bladder Cancer Therapy.
ACS Biomater Sci Eng. 2025 Aug 24. doi: 10.1021/acsbiomaterials.5c00960. PubMed Abstract available
RIZZO A, Valenti A Advancing age- and gender-sensitive supportive care and follow-up strategies in
bladder cancer.
Urol Oncol. 2025 Aug 23:S1078-1439(25)00276. PubMed
SILVA-FERREIRA M, Lopes-Conceicao L, Monteiro-Reis S, Henrique R, et al Reply to Hao Wang and Li Yang's Letter to the Editor re: Mariana Silva-Ferreira,
Joao A. Carvalho, Sofia Salta, et al. Diagnostic Test Accuracy of Urinary DNA
Methylation-based Biomarkers for Bladder Cancer: Considerations for Further
Research. Eur Ur
Eur Urol Focus. 2025 Aug 23:S2405-4569(25)00246. PubMed
YAN L, Su P, Sun X Role of the tumor microenvironment in promoting treatment resistance in
urothelial carcinoma (Review).
Mol Med Rep. 2025;32:293. PubMed Abstract available
KARLSSON L, Ek-Steinum A, Nyman V, Abuhasanein S, et al Patients' experiences of a standardized care pathway for suspected bladder cancer
due to macroscopic hematuria.
BMC Urol. 2025;25:216. PubMed Abstract available
LUO W, Chen Y, Shen D, Zhang Y, et al Emotional stress: a prominent factor positively related to the onset and
recurrence of bladder cancer as revealed by NHANES and a Chinese database.
Ann Med. 2025;57:2549525. PubMed Abstract available
YAU STY, Leung EYM, Hung CT, Wong MC, et al Interaction patterns amongst risk factors for bladder cancer in adults with type
2 diabetes managed in primary care.
BJGP Open. 2025 Aug 22:BJGPO.2025.0028. doi: 10.3399/BJGPO.2025.0028. PubMed Abstract available
STERNBERG CN, Squifflet P, Saad ED, Burdett S, et al Evaluating surrogates for overall survival in the adjuvant treatment of bladder
cancer with chemotherapy.
Urol Oncol. 2025 Aug 21:S1078-1439(25)00269. PubMed Abstract available
GOTO K, Kohada Y, Kobatake K, Tasaka R, et al Impact of the preoperative modified 5-item frailty index on the efficacy of
neoadjuvant chemotherapy in patients with muscle invasive bladder cancer.
Urol Oncol. 2025 Aug 21:S1078-1439(25)00283. PubMed Abstract available
TASAKA R, Kobatake K, Kohada Y, Takemoto K, et al KDM6A deficiency promotes 5-aminolevulinic acid-mediated photodynamic therapy
resistance in bladder cancer by suppressing ROS accumulation.
Urol Oncol. 2025 Aug 21:S1078-1439(25)00280. PubMed Abstract available
LI H, Zeng S, Yang C, Yang Y, et al Global, regional, and national burden and trends of bladder cancer in individuals
Aged 55 Years and older From 1990 to 2021: Findings from the Global Burden of
Disease Study 2021.
Int J Surg. 2025 Aug 21. doi: 10.1097/JS9.0000000000003254. PubMed Abstract available
ALANAZI F, Sharif A, Kidd M, Keevill EJ, et al Cell Surface Proteomics Reveals Hypoxia-Regulated Pathways in Cervical and
Bladder Cancer.
Proteomes. 2025;13:36. PubMed Abstract available
HU C, Wei S, Zhu W, Lv B, et al IRE1alpha modulates M1 oncolytic virus sensitivity via ER stress regulation in
bladder cancer.
Cancer Drug Resist. 2025;8:41. PubMed Abstract available
YANG B, Pan M, Tao T, Chen K, et al Tanshinone IIA promotes METTL3/METTL14-mediated FDX1 m6A modification to induce
cuproptosis in bladder cancer.
Toxicol Res (Camb). 2025;14:tfaf123. PubMed Abstract available
LI D, Xu JN, Chen HK, Ren Q, et al Comparative efficacy of holmium laser versus plasma techniques in the surgical
management of non-muscle invasive bladder cancer: a meta-analysis.
Front Oncol. 2025;15:1625901. PubMed Abstract available
JAIME-CASAS S, Zugman M, Barragan-Carrillo R, Ebrahimi H, et al Clinical and Pathological Predictors for Occult Lymph Node Involvement in
Patients With Clinical Node-Negative Bladder Cancer Undergoing Radical
Cystectomy.
Clin Genitourin Cancer. 2025 Jul 23:102405. doi: 10.1016/j.clgc.2025.102405. PubMed Abstract available
HE W, Wang M, Zhang C, Zeng S, et al Re: Thomas Dreyer, Simone Brandt, Fabrin Knud, et al. Use of the Xpert Bladder
Cancer Monitor for Guiding Cystoscopy in High-grade Non-muscle-invasive Bladder
Cancer: Results from the Randomized Controlled DaBlaCa-15 Trial. Eur Urol
2025;88:23-30.
Eur Urol Focus. 2025 Aug 20:S2405-4569(25)00250. PubMed
HIGGINS MI, Gabrielson AT, Su ZT, Feng M, et al Molecular classification of nonurothelial histologic subtypes of bladder cancer.
Urol Oncol. 2025 Aug 20:S1078-1439(25)00277. PubMed Abstract available
BOWIE K Bladder cancer: "Breakthrough" treatment that doubles survival rates is approved
for NHS patients.
BMJ. 2025;390:r1786. PubMed
SANO K, Shiga M, Ferdousi F, Sakurai H, et al A novel, synthesized, amphiphilic ethylene glycol squalene derivative suppresses
BBN-induced bladder carcinogenesis.
Sci Rep. 2025;15:30751. PubMed Abstract available
SARGOS P, Sauvage LM, Khalifa J, Riou O, et al Role of radiotherapy in the management of bladder cancer: Recommendations of the
French Society for Radiation Oncology, 2025 update.
Cancer Radiother. 2025;29. PubMed Abstract available
SHI Q, Pan X, Zhang S, Wu M, et al Menin facilitates the cell proliferation of bladder cancer via modulating the
TFAP2C/beta-catenin axis.
Genes Dis. 2025;12:101565. PubMed Abstract available
SUN FZ, Liu YX, Xu QL, Guo LX, et al Oncological outcome and survival predictors of widowed patients with bladder
cancer in special populations.
Sci Rep. 2025;15:30638. PubMed Abstract available
MATSUDA E, Hasebe S, Matsuzaka T, Hayashi A, et al Inhibition of ELOVL6 activity impairs mitochondrial respiratory function and
inhibits tumor progression in FGFR3-mutated bladder cancer cells.
Biochim Biophys Acta Mol Basis Dis. 2025;1871:168023. PubMed Abstract available
MACHADO M, Yim W, Strano MS A Sensor Solution to the Femtomolar Problem in Bladder Cancer.
ACS Sens. 2025 Aug 20. doi: 10.1021/acssensors.5c00670. PubMed Abstract available
OH C, Bourlotos G, O'Callaghan M, Grundy L, et al BCG Intolerance in Nonmuscle Invasive Bladder Cancer-A Systematic Review.
ANZ J Surg. 2025 Aug 20. doi: 10.1111/ans.70281. PubMed Abstract available
KONG L, Qin Y, Li H, Cai Q, et al Development and Validation of a Preoperative MRI Habitat Radiomics Model to
Predict Variant Histology in Bladder Cancer.
J Magn Reson Imaging. 2025 Aug 20. doi: 10.1002/jmri.70069. PubMed Abstract available
YE S, Liufu C, Yin C, Zhu T, et al MiR-20a-5p Inhibits Bladder Cancer Proliferation and Migration by Targeting
KPNA2.
J Cell Mol Med. 2025;29:e70785. PubMed Abstract available
SUN J, Yang H, Zhuang J, Chen R, et al Copper single-atom-based flexible aptamer biochip for simultaneous monitoring of
bladder cancer-related bacteria.
Mikrochim Acta. 2025;192:602. PubMed Abstract available
ECKE TH, Collen S, Filicevas A, Yfantis T, et al Urinary bladder cancer needs more attention - recommendations for health care
professionals and politicians in the European Union.
Nat Rev Urol. 2025 Aug 19. doi: 10.1038/s41585-025-01077. PubMed Abstract available
BORCSOK J, Gopaul D, Devesa-Serrano D, Mooser C, et al Quantitative functional profiling of ERCC2 mutations deciphers cisplatin
sensitivity in bladder cancer.
J Clin Invest. 2025;135:e186688. PubMed Abstract available
ZHAO Y, Wu X, Zheng Y, Bai H, et al Prognostic value of LncRNA DLGAP1-AS2 in bladder cancer and its regulatory effect
on tumor progression.
Discov Oncol. 2025;16:1578. PubMed Abstract available
SZYMKIEWICZ S Suspected Urine-Induced Chemical Peritonitis Secondary to Invasive Bladder
Cancer: A Case Report.
Cureus. 2025;17:e90092. PubMed Abstract available
SUARTZ CV, de Lima RD, de Almeida LS, Liebl B, et al Neoadjuvant Immunotherapy in Bladder Cancer: Ushering in a New Era of Treatment-A
Systematic Review of Current Evidence.
Eur Urol Open Sci. 2025;79:45-59. PubMed Abstract available
VAN KOEVERDEN SW, van Hoogstraten LM, de Rooij M, van der Leest M, et al Multiparametric MRI for local staging in patients with suspected muscle-invasive
bladder cancer: study protocol for a multicentre, non-inferiority randomised
controlled trial (the BladParadigm study).
BMJ Open. 2025;15:e100002. PubMed Abstract available
ZHANG M, Zhao Y, Hao D, Song Y, et al An interpretable CT-based deep learning model for predicting overall survival in
patients with bladder cancer: a multicenter study.
NPJ Precis Oncol. 2025;9:288. PubMed Abstract available
LU Y, Ye F, Han X, Wang Z, et al Integrated spatial transcriptome and metabolism study reveals metabolic
heterogeneity in human bladder cancer.
Cancer Gene Ther. 2025 Aug 16. doi: 10.1038/s41417-025-00947. PubMed Abstract available
YANG D, Mao W, Jiang L, Liu B, et al CALD1-derived circ-0003746 targeting miR-526b promotes EMT-mediated bladder
cancer progression.
Exp Cell Res. 2025 Aug 14:114710. doi: 10.1016/j.yexcr.2025.114710. PubMed Abstract available
EMTIAZI N, Zolfi E, Khaleghi Mehr F Genetic investigation in patients with histological variants of bladder cancer:
clinical implications.
Expert Rev Anticancer Ther. 2025 Aug 25:1-23. doi: 10.1080/14737140.2025.2548487 PubMed Abstract available
VELISKOVA M, Masarovicova D, Waczulikova I, Kollarik B, et al The role of spectral characteristics of urine in bladder cancer diagnostics.
Sci Rep. 2025;15:29979. PubMed Abstract available
ARITA Y, Edo H, Yoshida S Structured MRI assessment after neoadjuvant therapy for bladder cancer: the
emerging roles of NacVI-RADS and multimodal AI.
Eur Radiol. 2025 Aug 15. doi: 10.1007/s00330-025-11934. PubMed
PATEL AU, Atiya S, Song Y, Chu W, et al Novel liquid immunocytochemistry with machine learning analysis for bladder
cancer detection.
J Histotechnol. 2025 Aug 15:1-9. doi: 10.1080/01478885.2025.2546655. PubMed Abstract available
WANG L, Chen P, Liu H, Qin J, et al A nomogram integrating mutation signatures and clinical features for prognostic
stratification in bladder cancer.
Discov Oncol. 2025;16:1562. PubMed Abstract available
WANG Y, Song W, Feng C, Wu S, et al Correction: Multi-omics analysis unveils the predictive value of IGF2BP3/SPHK1
signaling in cancer stem cells for prognosis and immunotherapeutic response in
muscle-invasive bladder cancer.
J Transl Med. 2025;23:909. PubMed
DAI M, Yuan X, Sun C, Han R, et al The ETS transcription factor GABPA inhibits bladder cancer aggressiveness by
repressing extracellular matrix deposition and mechanotransduction signaling.
Cell Death Dis. 2025;16:618. PubMed Abstract available
FISCHER J, Fischer LA, Bensberg J, Bojko N, et al CBCT-based online adaptive radiotherapy of the bladder - geometrical and
dosimetrical considerations compared to conventional IGRT.
Radiat Oncol. 2025;20:128. PubMed Abstract available
LV Z, Zhao S, Wu H Correction: LIMA1 inhibits cisplatin resistance and malignant biological behavior
of bladder cancer cells by suppressing the Wnt/beta-catenin pathway.
BMC Med Genomics. 2025;18:130. PubMed
GAO H, Ren D, Giannico GA, Akgul M, et al Do urinary bladder smooth muscle neoplasms show morphologic and immunophenotypic
features of their uterine fumarate hydratase-deficient counterparts?
Ann Diagn Pathol. 2025;79:152536. PubMed Abstract available
LEE HJ, Gulati R, Sayar E, Patel RA, et al Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers:
Implications for HER2-Targeted Therapies.
Cancer Res Commun. 2025;5:1419-1428. PubMed Abstract available
HOFFMAN-CENSITS J, Tsiatas M, Chang PM, Kim M, et al Avelumab plus sacituzumab govitecan versus avelumab monotherapy as first-line
maintenance treatment in patients with advanced urothelial carcinoma: JAVELIN
Bladder Medley interim analysis.
Ann Oncol. 2025;36:1088-1095. PubMed Abstract available
GARJE R, Ravindra A, Rahim B, Kroll M, et al Avelumab and taxol chemotherapy in platinum-refractory or ineligible metastatic
urothelial carcinoma (AVETAX trial).
Urol Oncol. 2025;43:520. PubMed Abstract available
DAMAN AW, Antonelli AC, Redelman-Sidi G, Paddock L, et al Microbial cancer immunotherapy reprograms hematopoiesis to enhance myeloid-driven
anti-tumor immunity.
Cancer Cell. 2025;43:1442-1459. PubMed Abstract available
FADEL A, Findlay BL, Pinkhasov AM, Sharma V, et al Variability in Health Care Utilization and Perioperative Outcomes Among Urinary
Diversion Patients: Analysis of the National Surgical Quality Improvement Program
Database.
Urol Pract. 2025;12:548-556. PubMed Abstract available
TEPLITSKY SL, Cranford W, Kim JK, Bell S, et al Prognostic significance of pathologic response to neoadjuvant chemotherapy in
muscle-invasive urothelial carcinoma of the bladder with histologic subtype.
Urol Oncol. 2025;43:521. PubMed Abstract available
MEDINA C, Garcia V, Gutierrez A, Caicedo JI, et al Urachal actinomycosis mimicking a urachal adenocarcinoma: case report and
systematic review.
Lancet Infect Dis. 2025;25:e533-e539. PubMed Abstract available
ZHENG M, Lu J, Yu W, Li Y, et al Nucleoporin 188 as a Predictive Biomarker of Poor Prognosis in Muscle-invasive
Bladder Cancer.
Anticancer Res. 2025;45:3245-3261. PubMed Abstract available
OKADA K, Naito Y, Irie S, Nakamoto C, et al Novel UF-5000-based Detection, Integrating Inflammatory Parameters, for
Urothelial Carcinoma of the Urinary Bladder.
Anticancer Res. 2025;45:3531-3541. PubMed Abstract available
LONGONI M, Scilipoti P, Zaurito P, Moschini M, et al Response to Hof et al.: spurious associations between BCG instillations and
outcomes in non-muscle-invasive bladder cancer.
BJU Int. 2025 Jul 29. doi: 10.1111/bju.16867. PubMed
DEY L, Rautiola J, Akre O, Egevad L, et al Long-term oncological outcomes of bladder cancer: a population-based study with a
25-year follow-up.
BJU Int. 2025 Aug 7. doi: 10.1111/bju.16883. PubMed Abstract available
ZAURITO P, Scilipoti P, Longoni M, Viti A, et al The value of maintenance therapy in intermediate-risk non-muscle-invasive bladder
cancer.
BJU Int. 2025 Aug 22. doi: 10.1111/bju.16905. PubMed Abstract available
APOLO AB, Atiq S, Kydd AR, Chelluri R, et al Top advances of the year: Bladder cancer.
Cancer. 2025;131:e70020. PubMed Abstract available
CHEN C, Gao Y, Lu R, Wu Y, et al TERC Stimulates Fatty Acid Metabolism to Promote Bladder Cancer Progression.
Cancer Res. 2025 Aug 4. doi: 10.1158/0008-5472.CAN-24-3439. PubMed Abstract available
MASTROLEO F, Marvaso G, Jereczek-Fossa BA Artificial intelligence in muscle-invasive bladder cancer: opportunities,
challenges, and clinical impact.
Curr Opin Urol. 2025;35:543-548. PubMed Abstract available
GUERRERO-RAMOS F, Gomez-Canizo C, Hernandez-Arroyo M, Subiela JD, et al Hyperthermic intravesical chemotherapy for Bacillus Calmette-Guerin-unresponsive
nonmuscle-invasive bladder cancer.
Curr Opin Urol. 2025 Aug 14. doi: 10.1097/MOU.0000000000001329. PubMed Abstract available
BRACCO FM, Wong CHM, Teoh JYC Antibody-drug conjugates for non-muscle invasive bladder cancer: current status
and future development.
Curr Opin Urol. 2025 Aug 25. doi: 10.1097/MOU.0000000000001330. PubMed Abstract available
RIEGER C, Schluchtermann J, Heidenreich J, Steenbock O, et al Cost-effectiveness analysis of perioperative durvalumab plus platin-based
chemotherapy in muscle invasive bladder cancer in Germany.
Eur J Cancer. 2025;227:115621. PubMed Abstract available
GUO Y, Zhang W, Zhang J, Mao S, et al Re: Oncolytic Immunotherapy with Nivolumab in Muscle-invasive Bladder Cancer: A
Phase 1b Trial.
Eur Urol. 2025 Jul 28:S0302-2838(25)00406-3. doi: 10.1016/j.eururo.2025. PubMed
RAYCHAUDHURI R, Khaki AR, Redman MW, Baker KK, et al Neoadjuvant Pembrolizumab and Accelerated Methotrexate, Vinblastine, Doxorubicin,
and Cisplatin in Nonurothelial Histologic Subtypes of Muscle-invasive Bladder
Cancer: A Phase 2 Trial.
Eur Urol. 2025 Aug 4:S0302-2838(25)00391-4. doi: 10.1016/j.eururo.2025. PubMed Abstract available
GOTO Y Editorial Comment on "Recent Advances and Future Directions in Bladder
Preservation Therapy for Muscle-Invasive Bladder Cancer".
Int J Urol. 2025 Jul 27. doi: 10.1111/iju.70184. PubMed
WANG M, Jia B, Yang F, Han S, et al The Xing Technique for Intracorporeal Ileal Conduit: Outcomes From a Single
Center.
Int J Urol. 2025;32:1034-1038. PubMed Abstract available
WAKAMIYA T, Yamashita S, Kohjimoto Y, Hara I, et al Serum Lactate Dehydrogenase Level Prior to First-Line Chemotherapy for Metastatic
Urothelial Carcinoma Is a Prognostic Factor for Avelumab Maintenance Therapy: A
Multicenter Retrospective Study.
Int J Urol. 2025;32:997-1004. PubMed Abstract available
FUKUTA K, Daizumoto K, Sasaki Y, Izumi K, et al Geriatric Nutritional Risk Index Predicts Postoperative Complications in Elderly
Patients Undergoing Robot-Assisted Radical Cystectomy.
Int J Urol. 2025;32:944-950. PubMed Abstract available
KAWAHARA T Re: Recent Advances and Future Directions in Bladder Preservation Therapy for
Muscle-Invasive Bladder Cancer.
Int J Urol. 2025 Aug 14. doi: 10.1111/iju.70199. PubMed
XIANG X, Mei X, Song X, Pan B, et al High-density lectin microarray uncovers stage-specific plasma glycoprofiling
signatures for non-muscle-invasive and muscle-invasive bladder cancer.
Int Urol Nephrol. 2025 Aug 10. doi: 10.1007/s11255-025-04708. PubMed Abstract available
LIU X, Wang Y, Wang Z, Shao B, et al Chemotherapy-enhanced endoscopic submucosal En Bloc dissection vs. conventional
TURBT for NMIBC: a comparative study.
Int Urol Nephrol. 2025;57:2755-2765. PubMed Abstract available
DANESHMAND S, Van der Heijden MS, Jacob JM, Guerrero-Ramos F, et al TAR-200 for Bacillus Calmette-Guerin-Unresponsive High-Risk Non-Muscle-Invasive
Bladder Cancer: Results From the Phase IIb SunRISe-1 Study.
J Clin Oncol. 2025 Jul 30:101200JCO2501651. doi: 10.1200/JCO-25-01651. PubMed Abstract available
GALSKY MD, Ballas L, Kamat AM Muscle-Invasive Bladder Cancer: A Watershed Moment.
J Clin Oncol. 2025 Aug 5:JCO2500718. doi: 10.1200/JCO-25-00718. PubMed Abstract available
HU H, Zhan X, Xiong Y, Yuan R, et al Retraction Note: Non-classic deubiquitinase USP13 inhibits bladder cancer
metastasis through destabilizing cytoplasmic KDM3A.
Oncogene. 2025 Jul 30. doi: 10.1038/s41388-025-03520. PubMed
ELLEISY M, Zettl H, Drager DL, Hakenberg OW, et al The Impact of Diabetes and Antidiabetics on Uro-Oncological Disease Outcomes: A
Single-Center Experience.
Urol Int. 2025;109:361-371. PubMed Abstract available
YANG Y, Holbach S, Haas M, Engelmann SU, et al Does Time Matter in Early Radical Cystectomy? Comparing Outcome, Clinical, and
Pathological Characteristics of Immediate versus Deferred Radical Cystectomy.
Urol Int. 2025;109:315-322. PubMed Abstract available
AL-NADER M, Krafft U, Darr C, Hess J, et al Outcomes of Surgical Therapy for Local Recurrence and Oligometastatic Urothelial
Carcinoma of the Bladder: 20 Years of Experience in a Tertiary Center.
Urol Int. 2025;109:337-345. PubMed Abstract available
SCHNEIDEWIND L, Kiss B, Kranz J, Zengerling F, et al Gender-Specific Differences in Recurrence and Progression following Bacillus
Calmette-Guerin Instillation for Non-Muscle-Invasive Bladder Cancer.
Urol Int. 2025;109:412-424. PubMed Abstract available
OBIORA D, Yu M, Sharbaugh D, Bandari J, et al Treatment Patterns for Non-Muscle Invasive Bladder Cancer during the Bacillus
Calmette-Guerin shortage.
Urology. 2025 Jul 23:S0090-4295(25)00711-3. doi: 10.1016/j.urology.2025. PubMed Abstract available
SMITH AB, Gore JL, Chisolm S, Squires P, et al Muscle-Invasive Bladder Cancer Treatment Selection in an Emerging Treatment Era:
A Patient Preference Study.
Urology. 2025 Aug 12:S0090-4295(25)00767-8. doi: 10.1016/j.urology.2025. PubMed Abstract available
HU C, Wang F, Xu H, Dong X, et al Deep learning-based spatial analysis on tumor and immune cells of pathology
images predicts MIBC prognosis.
PLoS One. 2025;20:e0328816. PubMed Abstract available
